<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOTEMAX- loteprednol etabonate gel </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LOTEMAX<span class="Sup">® </span> (loteprednol etabonate ophthalmic gel) 0.5% safely and effectively.  See full prescribing information for LOTEMAX<span class="Sup">®</span>.<br><br><br>LOTEMAX<span class="Sup">® </span>(loteprednol etabonate ophthalmic gel) 0.5% <br>Initial U.S. Approval: 1998</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">LOTEMAX is a corticosteroid indicated for the treatment of post-operative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following ocular surgery. (<a href="#i4i_indications_id_860cbf98-f196-4743-bf5f-5cc3d7219c6d">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Invert closed bottle and shake once to fill tip before instilling drops.<br><br> </p>
<p class="Highlighta">Apply one to two drops of LOTEMAX into the conjunctival sac of the affected eye four times daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period. (<a href="#i4i_dosage_admin_id_2dda1047-8719-433c-af56-83cd70921beb">2</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">LOTEMAX contains 5 mg/g of loteprednol etabonate, as a sterile preserved ophthalmic gel. (<a href="#i4i_dosage_form_strength_id_260e17c8-51cc-48c1-aa38-49cf84dbe83e">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">LOTEMAX, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures. (<a href="#i4i_contraindications_id_19aa3838-f401-443c-a95a-c3d71bc050d1">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Intraocular pressure (IOP) increase - Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored. (<a href="#i4i_section_id_fc45ea3b-ec32-41e7-835c-8b925c422515">5.1</a>)<br><br>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span>- Use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. (<a href="#i4i_section_id_cdccd923-dd18-4000-96c4-2e37db0b89c0">5.2</a>)<br><br>
</dd>
<dt>•</dt>
<dd>Delayed healing–The use of steroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.  The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. (<a href="#i4i_section_id_317c9a25-fc7c-4fac-bde2-ce3eb4cf313a">5.3</a>)<br><br>
</dd>
<dt>•</dt>
<dd>Bacterial infections–Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. In acute purulent conditions, steroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#i4i_section_id_2a638098-f5f0-444d-84b1-2252840f1de0">5.4</a>)<br><br>
</dd>
<dt>•</dt>
<dd>Viral infections–Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex). (<a href="#i4i_section_id_67302d62-f12a-4672-87b6-b4d19c38e5ef">5.5</a>)<br><br>
</dd>
<dt>•</dt>
<dd>Fungal infections–<span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where a steroid has been used or is in use. (<a href="#i4i_section_id_2b9b6c85-2611-4f86-855e-d7406c8bbea0">5.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> The most common adverse drug reactions were anterior chamber <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (5%), <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> (2%), and foreign body sensation (2%). (<a href="#i4i_adverse_effects_id_674b0b61-3026-490b-a14d-e4113dfbefec">6</a>)<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb at 1-800-323-0000 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Intraocular Pressure (IOP) Increase</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Delayed Healing</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Contact Lens Wear</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Administration</a></h2>
<h2><a href="#section-13.2" class="toc">17.2 Risk of Contamination</a></h2>
<h2><a href="#section-13.3" class="toc">17.3 Contact Lens Wear</a></h2>
<h2><a href="#section-13.4" class="toc">17.4 Risk of <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary Infection</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_860cbf98-f196-4743-bf5f-5cc3d7219c6d"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LOTEMAX<span class="Bold"><span class="Sup">®</span></span> is a corticosteroid indicated for the treatment of post-operative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following ocular surgery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2dda1047-8719-433c-af56-83cd70921beb"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Invert closed bottle and shake once to fill tip before instilling drops.</p>
<p>Apply one to two drops of LOTEMAX into the conjunctival sac of the affected eye four times daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period. </p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_260e17c8-51cc-48c1-aa38-49cf84dbe83e"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">LOTEMAX (loteprednol etabonate ophthalmic gel) 0.5% contains 5 mg/g of loteprednol etabonate, as a sterile preserved ophthalmic gel.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_19aa3838-f401-443c-a95a-c3d71bc050d1"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">LOTEMAX, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_7183204f-3d1c-43e1-9020-f6cdd651107a"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc45ea3b-ec32-41e7-835c-8b925c422515"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Intraocular Pressure (IOP) Increase</h2>
<p class="First">Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. If this product is used for 10 days or longer, intraocular pressure should be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdccd923-dd18-4000-96c4-2e37db0b89c0"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></h2>
<p class="First">Use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation<span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_317c9a25-fc7c-4fac-bde2-ce3eb4cf313a"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Delayed Healing</h2>
<p class="First">The use of steroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a638098-f5f0-444d-84b1-2252840f1de0"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span></h2>
<p class="First">Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In acute purulent conditions of the eye, steroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67302d62-f12a-4672-87b6-b4d19c38e5ef"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></h2>
<p class="First">Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b9b6c85-2611-4f86-855e-d7406c8bbea0"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96c59267-6184-42eb-880c-98bcae7da708"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Contact Lens Wear</h2>
<p class="First">Patients should not wear contact lenses during their course of therapy with LOTEMAX.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_674b0b61-3026-490b-a14d-e4113dfbefec"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, visual acuity and field defects, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation, delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing and secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.</p>
<p>The most common adverse drug reactions reported were anterior chamber <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (5%), <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> (2%), and foreign body sensation (2%).</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_eed2f0d1-99d4-4775-9407-0a0fecaea413"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_a9825b8a-6d83-4c99-896e-cb77b240fba5"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic Effects:Pregnancy Category C.</span></p>
<p>Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of <span class="product-label-link" type="condition" conceptid="4062639" conceptname="Meningocele">meningocele</span>, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose). Oral treatment of rats during organogenesis resulted in <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> (absent innominate artery at ≥5 mg/kg/day doses, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span> at ≥50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with ≥50 mg/kg/day). Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity. Loteprednol etabonate was maternally toxic (significantly reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during treatment) when administered to pregnant rats during organogenesis at doses of ≥5 mg/kg/day.</p>
<p>Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; the NOEL for these effects was 5 mg/kg/day<span class="Bold">. </span>Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period.</p>
<p>There are no adequate and well controlled studies in pregnant women.  LOTEMAX<span class="Sup">® </span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_0e607001-1cd8-4eb6-8009-d6d4b44124f3"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when LOTEMAX is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_811d1ddb-3468-40b4-bbab-919614590047"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_f99eda2e-9a55-4bfc-8fb4-9b4547d9a05a"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall differences in safety and effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_2b605400-34f7-440a-ab73-deedfa9fef47"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">LOTEMAX (loteprednol etabonate ophthalmic gel) 0.5% contains a sterile, topical corticosteroid for ophthalmic use. Loteprednol etabonate is a white to off-white powder.</p>
<p>Loteprednol etabonate is represented by the following structural formula:</p>
<div class="Figure">
<a name="id459"></a><img alt="Loteprednol etabonate structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a666065-d467-42b8-8ecd-0ec1de9986d5&amp;name=9a666065-d467-42b8-8ecd-0ec1de9986d5-01.jpg">
</div>
<p>Chemical Name:</p>
<p>chloromethyl 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate</p>
<p><span class="Bold">Each gram contains:</span></p>
<p>ACTIVE: Loteprednol Etabonate 5 mg (0.5%);</p>
<p>INACTIVES: Boric acid, edetate disodium dihydrate, glycerin, polycarbophil, propylene glycol, sodium chloride, tyloxapol, water for injection, and sodium hydroxide to adjust to a pH of between 6 and 7.</p>
<p>PRESERVATIVE: benzalkonium chloride 0.003%.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e50b7f8f-9bea-4f9e-99c6-30a391b00dba"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_ca4cc77d-c034-44de-ba88-635fa2f73090"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> formation associated with <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> are not clearly established.  However, corticosteroids are thought to inhibit prostaglandin production through several independent mechanisms.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_c7185617-4dab-4f60-aec8-609c8d4e97f9"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Loteprednol is lipid soluble and can penetrate into cells.  Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon <span class="Italics">in vivo </span>and <span class="Italics">in vitro </span>preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to the inactive carboxylic acid metabolites, PJ-91 and PJ-90. The systemic exposure to loteprednol etabonate following ocular administration of LOTEMAX has not been studied in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_4a73d5b1-1fdb-492e-9050-cdd1ab9a18d3"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b8f923e5-317b-404e-b7c6-851b08da3ac1"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate.  Loteprednol etabonate was not genotoxic <span class="Italics">in vitro </span>in the Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> tk assay, or in a chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, or <span class="Italics">in vivo </span>in the single dose mouse micronucleus assay. Treatment of male and female rats with up to 50 mg/kg/day and 25 mg/kg/day of loteprednol etabonate, respectively, (600 and 300 times the maximum clinical dose, respectively) prior to and during mating did not impair fertility in either gender.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_443f2a57-bde2-48a0-9c0d-ab5ba552e8b6"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In two randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies in 813 subjects with, post-operative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, LOTEMAX was more effective compared to its vehicle in resolving anterior chamber <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery. Primary endpoints were complete resolution of <span class="product-label-link" type="condition" conceptid="4081011" conceptname="Anterior chamber cells">anterior chamber cells</span> (cell count of 0) and no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at post-operative day 8. </p>
<p>In these studies, LOTEMAX had a statistically significant higher incidence of subjects with complete clearing of <span class="product-label-link" type="condition" conceptid="4081011" conceptname="Anterior chamber cells">anterior chamber cells</span> (31% vs. 14-16%)  and were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> free at post-operative day 8 (73-76% vs. 42-46%).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_7548bea6-ecd6-445c-9ad5-dfff5cab12ae"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">LOTEMAX<span class="Bold"><span class="Sup">®</span></span> (loteprednol etabonate ophthalmic gel) 0.5% is a sterile ophthalmic gel supplied in a white low density polyethylene plastic bottle with a white controlled drop tip and a pink polypropylene cap in the following size:</p>
<p>5 g in a 10 mL bottle (NDC 24208-503-07)</p>
<p>Use only if imprinted neckband is intact.</p>
<p><span class="Bold">Storage:</span> Store upright at 15º-25º C (59º-77º F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_98c487d2-da54-44dd-b55f-d3b6848fcb1e"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f15569f-52d3-4ba7-88ff-cb3801bea145"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Administration</h2>
<p class="First">Invert closed bottle and shake once to fill tip before instilling drops.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35672cba-d31f-4738-9f27-4ea26ed09d44"></a><a name="section-13.2"></a><p></p>
<h2>17.2 Risk of Contamination</h2>
<p class="First">Patients should be advised not to allow the dropper tip to touch any surface, as this may contaminate the gel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56ee978b-82d7-4b8d-a5dd-36f9d4d00b5e"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Contact Lens Wear</h2>
<p class="First">Patients should be advised not to wear contact lenses when using LOTEMAX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02477c37-305e-499a-b6f9-e01460a575ff"></a><a name="section-13.4"></a><p></p>
<h2>17.4 Risk of <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary Infection</span></h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> develops, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> becomes aggravated, the patient should be advised to consult a physician.<br><br><br><br></p>
<p>Bausch &amp; Lomb Incorporated<br>Tampa, Florida 33637 USA</p>
<p>US Patent No. 5,800,807</p>
<p>©Bausch &amp; Lomb Incorporated<br>®/™ are trademarks of Bausch &amp; Lomb Incorporated or its affiliates.</p>
<p>Reference ID: 3196435</p>
<p>9269100 Flat</p>
<p>9269200 Folded</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8746597c-7b19-483e-b439-617ee180489e"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id603"></a><img alt="LOTEMAX® (loteprednol etabonate ophthalmic gel) 0.5% label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a666065-d467-42b8-8ecd-0ec1de9986d5&amp;name=9a666065-d467-42b8-8ecd-0ec1de9986d5-02.jpg">
</div>
<p class="First">NDC 24208-503-07</p>
<p>BAUSCH + LOMB</p>
<p><span class="Bold">LOTEMAX<span class="Sup">®</span></span></p>
<p><span class="Bold">loteprednol etabonate</span><br><span class="Bold">ophthalmic gel 0.5%</span></p>
<p><span class="Bold">Sterile</span></p>
<p><span class="Bold">Rx only</span></p>
<p>5 g</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTEMAX 		
					</strong><br><span class="contentTableReg">loteprednol etabonate gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-503</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LOTEPREDNOL ETABONATE</strong> (LOTEPREDNOL) </td>
<td class="formItem">LOTEPREDNOL ETABONATE</td>
<td class="formItem">5 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYCARBOPHIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TYLOXAPOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-503-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 g in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-503-48</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">0.5 g in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202872</td>
<td class="formItem">10/12/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-503)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9344a866-e4c1-48e6-82ca-482fb001a9c5</div>
<div>Set id: 9a666065-d467-42b8-8ecd-0ec1de9986d5</div>
<div>Version: 5</div>
<div>Effective Time: 20141028</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
